Currently, more than 25
million people worldwide live with AD. But there is no cure for AD and no
treatment to reverse its progression, there are medicines available that can
help treat symptoms in some people with this disease. Intensive scientific
research around the world brings us closer to understanding the causes of AD on
molecular level. Taking into account AD complexity, it becomes clear that
polypharmacology with drugs targeting different molecules could be the future
treatment approach.
Otava offers 29 Alzheimer’s disease
Targeted Libraries designed with Ligand-based and
Receptor-based approach. These libraries contain only drug-like compounds. All
molecules have enhanced potential for CNS bioavailability. Filtering by polar
surface area parameter (PSA) which discriminates CNS penetrating compounds, we
selected only those compounds having increased blood-brain barrier (BBB) permeability.
In this collection of targeted libraries we included
those activities which can be divided into two Alzheimer’s treatment
categories: (i) disease-modifying treatments that target and reduce the
secondary pathologies of the disease, leading to the cessation or the reversal
of disease progression; and (ii) symptomatic treatments that treat cognitive
symptoms of the disease and protect from further cognitive decline.
We hope that Otava Targeted Libraries can help scientists and pharmaceutical
companies racing to develop treatments that address the underlying Alzheimer’s disease
processes.
Otava Ltd.
P.O. Box 88
Kyiv 187, 03187
Ukraine
Phone/Fax : +380 44 522 24 58
http://www.otavachemicals.com/